Meag Munich Ergo, Kapitalanlagegesellschaft Mb H Gilead Sciences, Inc. Transaction History

Meag Munich Ergo, Kapitalanlagegesellschaft Mb H

$2.96 Billion
Q2 2024

A detailed history of Meag Munich Ergo, Kapitalanlagegesellschaft Mb H transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Meag Munich Ergo, Kapitalanlagegesellschaft Mb H holds 964,066 shares of GILD stock, worth $75.9 Million. This represents 2.24% of its overall portfolio holdings.

Number of Shares

964,066

Previous 876,899 9.94%

Holding current value

$75.9 Million

Previous $64.2 Million 2.98%

% of portfolio

2.24%

Previous 2.38%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	BUY	$63.15 - $72.88 $5.5 Million - $6.35 Million	87,167 Added 9.94%	964,066 $66.1 Million
Q1 2024 Apr 18, 2024	SELL	$71.58 - $87.29 $578,795 - $705,826	-8,086 Reduced 0.91%	876,899 $64.2 Million
Q4 2023 Jan 19, 2024	BUY	$73.27 - $83.09 $19.4 Million - $22 Million	264,282 Added 42.58%	884,985 $71.7 Million
Q3 2023 Oct 25, 2023	BUY	$73.94 - $80.67 $8.57 Million - $9.35 Million	115,865 Added 22.95%	620,703 $46.5 Million
Q2 2023 Jul 14, 2023	BUY	$76.01 - $86.7 $36.8 Million - $42 Million	484,502 Added 2382.48%	504,838 $38.9 Million
Q1 2023 Apr 20, 2023	SELL	$77.31 - $88.08 $1 Million - $1.14 Million	-12,998 Reduced 38.99%	20,336 $1.69 Million
Q4 2022 Jan 19, 2023	BUY	$62.32 - $89.47 $1.16 Million - $1.66 Million	18,554 Added 125.53%	33,334 $2.86 Million
Q3 2022 Oct 18, 2022	SELL	$59.54 - $68.01 $208,390 - $238,035	-3,500 Reduced 19.15%	14,780 $912,000
Q2 2022 Jul 19, 2022	BUY	$57.72 - $65.01 $622,221 - $700,807	10,780 Added 143.73%	18,280 $1.13 Million
Q1 2022 Apr 13, 2022	BUY	$57.92 - $72.58 $191,136 - $239,514	3,300 Added 78.57%	7,500 $451,000
Q3 2021 Oct 13, 2021	SELL	$67.69 - $73.03 $2.35 Million - $2.53 Million	-34,693 Reduced 89.2%	4,200 $293,000
Q2 2021 Jul 16, 2021	SELL	$63.47 - $69.35 $1.11 Million - $1.22 Million	-17,547 Reduced 31.09%	38,893 $2.68 Million
Q1 2021 Apr 20, 2021	BUY	$60.0 - $68.46 $1.32 Million - $1.5 Million	21,970 Added 63.74%	56,440 $3.65 Million
Q4 2020 Jan 20, 2021	BUY	$56.65 - $64.55 $339,900 - $387,300	6,000 Added 21.07%	34,470 $1.95 Million
Q3 2020 Oct 20, 2020	BUY	$62.1 - $78.08 $477,300 - $600,122	7,686 Added 36.98%	28,470 $1.8 Million
Q2 2020 Jul 16, 2020	SELL	$72.34 - $84.0 $873,143 - $1.01 Million	-12,070 Reduced 36.74%	20,784 $1.6 Million
Q1 2020 Apr 23, 2020	SELL	$62.63 - $80.22 $3.81 Million - $4.87 Million	-60,766 Reduced 64.91%	32,854 $2.46 Million
Q4 2019 Jan 17, 2020	SELL	$61.62 - $67.78 $2.29 Million - $2.52 Million	-37,214 Reduced 28.44%	93,620 $6.08 Million
Q3 2019 Oct 29, 2019	BUY	$62.51 - $69.0 $3.74 Million - $4.13 Million	59,865 Added 84.35%	130,834 $8.2 Million
Q2 2019 Jul 17, 2019	BUY	$61.87 - $69.38 $1.33 Million - $1.49 Million	21,540 Added 43.58%	70,969 $4.77 Million
Q1 2019 Apr 29, 2019	SELL	$62.53 - $70.05 $3.09 Million - $3.47 Million	-49,481 Reduced 50.03%	49,429 $3.15 Million
Q4 2018 Jan 29, 2019	BUY	$60.54 - $79.0 $548,250 - $715,424	9,056 Added 10.08%	98,910 $6.24 Million
Q3 2018 Oct 23, 2018	BUY	$71.28 - $78.92 $1.21 Million - $1.34 Million	17,027 Added 23.38%	89,854 $6.84 Million
Q2 2018 Jul 17, 2018	SELL	$64.88 - $75.68 $2.32 Million - $2.71 Million	-35,751 Reduced 32.93%	72,827 $5.17 Million
Q1 2018 May 02, 2018	BUY	$72.84 - $88.8 $421,525 - $513,885	5,787 Added 5.63%	108,578 $8.09 Million
Q4 2017 Jan 26, 2018	SELL	$71.15 - $83.52 $18.6 Million - $21.8 Million	-260,952 Reduced 71.74%	102,791 $7.49 Million
Q3 2017 Nov 06, 2017	BUY	$72.11 - $85.47 $26.2 Million - $31.1 Million	363,743	363,743 $29.5 Million

Others Institutions Holding GILD

# of Institutions

1,879

Shares Held

1.02B

Call Options Held

12M

Put Options Held

8.96M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $98.7B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Meag Munich Ergo, Kapitalanlagegesellschaft Mb H, based on Form 13F filings with the SEC.

News

Stay updated on Meag Munich Ergo, Kapitalanlagegesellschaft Mb H with notifications on news.

Account

Meag Munich Ergo, Kapitalanlagegesellschaft Mb H Gilead Sciences, Inc. Transaction History